TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01133106

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief pleasurable events/behavioral therapy
Description: Each participant in any arm will be given an American Stroke Association article about stroke and depression, a Stroke Smart Article about caregiver depression, and a pamphlet by the Beck Institute titled Coping with Depression.~Each participant in Arms 1 and 2 will be given their own manual for the intervention sessions. The intervention consists of one in-person orientation session and 6 weekly sessions with the following topics introducing behavioral therapy, the role of pleasant events, problem-solving skills and generalization techniques. All participants' primary care provider or stroke care provider will receive a letter informing them of their patient's participation (but not of study assignment). This letter will include recommendations for prescribing and adjusting antidepressant treatment using established guidelines adapted for treatment of medically-ill outpatients.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief pleasurable events/behavioral therapy
Description: Each participant in any arm will be given an American Stroke Association article about stroke and depression, a Stroke Smart Article about caregiver depression, and a pamphlet by the Beck Institute titled Coping with Depression.~Each participant in Arms 1 and 2 will be given their own manual for the intervention sessions. The intervention consists of one in-person orientation session and 6 weekly sessions with the following topics introducing behavioral therapy, the role of pleasant events, problem-solving skills and generalization techniques. All participants' primary care provider or stroke care provider will receive a letter informing them of their patient's participation (but not of study assignment). This letter will include recommendations for prescribing and adjusting antidepressant treatment using established guidelines adapted for treatment of medically-ill outpatients.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: The standard care group (Arm C, N=75) will receive standard medical treatment from their provider, including a recommendation for antidepressants. Participants or third-party payers will pay for their antidepressants, just as they would under regular care. All participants receive written materials regarding depression from the American Stroke Association, keep medication logs and receive follow-up assessment on the same time frame as the intervention groups
Study: NCT01155609

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: management of therapy complications
Description: Discontinue supplement; treat symptomatically

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-lysine
Description: Given PO
Study: NCT04463030

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal vitamin C, 1 gram
Description: after a blood draw 1 gram of vitamin c will be consumed followed by 3 additional blood draws
Study: NCT02810327

Intervention type: GENETIC
Intervention: Genetic Sequencing
Description: Sequencing of the SERPINA1 gene

Intervention type: GENETIC
Intervention: Genetic Sequencing
Description: Sequencing of the SERPINA1 gene
Study: NCT03251599

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Glyceryl trinitrate 0.2
Description: These patients will receive glyceryl trinitrate infusion at a rate of 0.2 mcg/kg/min throughout the rewarming period of cardiopulmonary bypass, which usually lasts for 30-45 minutes.
Study: NCT04463030

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal vitamin C, 2 grams
Description: after a blood draw 2 grams of vitamin c will be consumed followed by 3 additional blood draws
Study: NCT03251599

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glyceryl trinitrate 0.5
Description: These patients will receive glyceryl trinitrate infusion at a rate of 0.5 mcg/kg/min throughout the rewarming period of cardiopulmonary bypass, which usually lasts for 30-45 minutes.
Study: NCT00756834

Intervention type: DEVICE
Intervention: Screening
Description: The MammoDetector™ Pro is a computer-aided software intended to identify and mark regions of interest on standard mammographic views to bring them to the attention of the radiologist after the initial reading has been completed. Thus, the device assists the radiologist in minimizing observational oversights by identifying areas on the original mammogram that may warrant a second review

Intervention type: DEVICE
Intervention: Screening
Description: The MammoDetector™ Pro is a computer-aided software intended to identify and mark regions of interest on standard mammographic views to bring them to the attention of the radiologist after the initial reading has been completed. Thus, the device assists the radiologist in minimizing observational oversights by identifying areas on the original mammogram that may warrant a second review
Study: NCT03395990

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Active comparator: chloroprocaine
Description: 15 ml of 2% chloroprocaine was placed under ultrasound guidance adjacent to the femoral nerve in the operative limb.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham comparator: saline
Description: 15 ml of normal saline was placed under ultrasound guidance adjacent to the femoral nerve in the operative limb.
Study: NCT04687397

Intervention type: BEHAVIORAL
Intervention: Rehabilitation
Description: Multidisciplinary rehabilitation
Study: NCT01967277

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Handi-Dome Laser
Description: One, 30 minute treatment, every other day for 16 weeks.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Incandescent red light source.
Description: One, 30 minute treatment, every other day for 16 weeks.
Study: NCT02949453

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Semi-directed interview performed by a social sciences researcher
Description: Two semi-directed interviews performed by social sciences researcher:~* first interview performed 6 weeks after the suicide attempt, in an suicide prevention unit, duration 1 to 1.5 hour~* second interview performed 3 month after the suicide attempt, in a suicide prevention unit, duration 1 to 1.5 hour
Study: NCT01967875

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine+Cisplatin
Description: Cisplatin 75mg/m2, d1; Capecitabine 1700-2000mg/m2/day on days1-14 every 21 days, 6 cycles.Capecitabine is to be continued until disease progression or intolerable toxicity.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine+Cisplatin
Description: Cisplatin 75mg/m2, d1; Capecitabine 1700-2000mg/m2/day on days1-14 every 21 days, 6 cycles.Capecitabine is to be continued until disease progression or intolerable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel+Capecitabine
Description: Docetaxel 75mg/m2, d1; Capecitabine 1700-2000mg/m2/day on days1-14 every 21 days, 6 cycles. Capecitabine is to be continued until disease progression or intolerable toxicity.
Study: NCT01281306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696
Description: LCZ696 was supplied as tablets in blister cards in 100 mg strengths.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Description: Valsartan was supplied as tablets in blister cards in 160 mg and 320 mg strengths.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Description: Valsartan was supplied as tablets in blister cards in 160 mg and 320 mg strengths.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Description: Valsartan was supplied as tablets in blister cards in 160 mg and 320 mg strengths.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Description: Valsartan was supplied as tablets in blister cards in 160 mg and 320 mg strengths.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Description: Valsartan was supplied as tablets in blister cards in 160 mg and 320 mg strengths.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AHU377
Description: AHU377 was supplied in tablets in blister cards in 50 mg and 100 mg strengths.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AHU377
Description: AHU377 was supplied in tablets in blister cards in 50 mg and 100 mg strengths.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AHU377
Description: AHU377 was supplied in tablets in blister cards in 50 mg and 100 mg strengths.
Study: NCT03958630

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET) Scan
Description: Participants underwent PET scan with \[11C\]ER176 and/or 11C-PIB

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET) Scan
Description: Participants underwent PET scan with \[11C\]ER176 and/or 11C-PIB

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET) Scan
Description: Participants underwent PET scan with \[11C\]ER176 and/or 11C-PIB
Study: NCT04250961

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: postoperative early shower
Description: The shower group showered in 48-72 hours after median sternotomy with tap water.
Study: NCT04463030

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal vitamin C, 5 grams
Description: after a blood draw 5 grams of vitamin c will be consumed followed by 3 additional blood draws

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: after a blood draw placebo will be consumed followed by 3 additional blood draws
Study: NCT01057121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide is administered daily on days 1-21 of a 28-day cycle. The maximum duration of treatment is 12 28-day cycles. Sequential cohorts were entered at 10 mg/day, 15 mg/day, 20 mg/day and 25 mg/day using a 3+3 design to determine the MTD
Study: NCT00761540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Liraglutide for s.c. injection once daily: dose step 1 (9 subjects)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Liraglutide placebo for s.c. injection once daily: dose step 1 (3 subjects)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Liraglutide for s.c. injection once daily: dose step 1, followed by dose step 2 (9 subjects)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Liraglutide placebo for s.c. injection once daily: dose step 1, followed by dose step 2 (3 subjects)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Liraglutide for s.c. injection once daily: dose step 1, followed by dose steps 2 and 3 (9 subjects)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Liraglutide placebo for s.c. injection once daily: dose step 1, followed by dose steps 2 and 3 (3 subjects)
Study: NCT03880396

Intervention type: RADIATION
Intervention: hypofractionated Rth with platinol
Description: hypofractionated Rth with weekly cisplatin 40mg/m2
Study: NCT03654547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TT-00420
Description: TT-00420 is an investigational, oral, multi-target, dual mechanism kinase inhibitor targeting both mitosis and tumor microenvironment, for the treatment of triple negative breast cancer (TNBC) and other advanced solid tumors.~TT-00420 capsule will be administered once daily on a continuous schedule. A treatment cycle consists of 28 days.~The proposed dosage form for early clinical research is powder filled hard gelatin capsule (PIC) with dosage strengths as of 1 mg, 5 mg and 20 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TT-00420
Description: TT-00420 is an investigational, oral, multi-target, dual mechanism kinase inhibitor targeting both mitosis and tumor microenvironment, for the treatment of triple negative breast cancer (TNBC) and other advanced solid tumors.~TT-00420 capsule will be administered once daily on a continuous schedule. A treatment cycle consists of 28 days.~The proposed dosage form for early clinical research is powder filled hard gelatin capsule (PIC) with dosage strengths as of 1 mg, 5 mg and 20 mg.
Study: NCT05784090

Intervention type: OTHER
Intervention: blood and saliva sample and lumbar puncture diagnostic for specific neurological diseases
Description: Saliva was collected using Salivettes (Sarsted, Newton, NC, USA) in dim light. CSF was obtained in the morning after overnight fasting by lumbar puncture at the L3/L4 or L4/L5 interspace.~Blood samples were drawn in fasting conditions. Plasma was separated by centrifugation.

Intervention type: OTHER
Intervention: blood and saliva sample and lumbar puncture diagnostic for specific neurological diseases
Description: Saliva was collected using Salivettes (Sarsted, Newton, NC, USA) in dim light. CSF was obtained in the morning after overnight fasting by lumbar puncture at the L3/L4 or L4/L5 interspace.~Blood samples were drawn in fasting conditions. Plasma was separated by centrifugation.

Intervention type: OTHER
Intervention: blood and saliva sample and lumbar puncture diagnostic for specific neurological diseases
Description: Saliva was collected using Salivettes (Sarsted, Newton, NC, USA) in dim light. CSF was obtained in the morning after overnight fasting by lumbar puncture at the L3/L4 or L4/L5 interspace.~Blood samples were drawn in fasting conditions. Plasma was separated by centrifugation.
Study: NCT01715025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2Nomac
Description: Women will start the first cycle of the COC on the first day of their period in the treatment phase of the study
Study: NCT04345549

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualised Ayurveda
Description: Saline warm water gargle, Steam, Paracetamol for body temperature and plenty fluid and rest, Food and herbs recommendation as per individual Ayurveda constitution, Using Ginger/ lemon/ turmeric/ honey recommended as per individual, Yoga breathing
Study: NCT05776537

Intervention type: DEVICE
Group type: OTHER
Intervention: Fibreoptic bronchoscopy
Description: different endoscopies used for confirmation of diagnosis
Study: NCT04250961

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: postoperative early shower
Description: The shower group showered in 48-72 hours after median sternotomy with tap water.
Study: NCT00734513

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Partner-assisted emotional disclosure
Description: Patients and partners in the partner-assisted emotional disclosure condition will attend four weekly face-to-face sessions with a therapist. The first session will last 75 minutes and will focus on training in skills to facilitate the patient's disclosure. The subsequent 3 sessions will last 45 minutes each. In these sessions, the therapist will briefly review the strategies and provide feedback from the previous session and the patient will spend 30 minutes talking about their cancer-related concerns to the partner.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cancer Education
Description: The cancer education protocol consists of four weekly face-to-face sessions for education about living with GI cancer. The cancer education sessions will be delivered to patients and their partners and use a presentation and discussion format. Handouts and discussion sessions will center on the following topics: Orientation to Duke Cancer Care and the treatment team; suggestions for communicating with health care providers; resources for health information, psychosocial support, and financial concerns; evaluating health information on the internet; the impact of cancer on different domains of quality of life; and suggestions for maintaining quality of life.
Study: NCT03576027

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen Therapy
Description: Hyperbaric Oxygen Therapy
Study: NCT03442803

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Target-Controlled Infusion
Description: Propofol Target-Controlled Infusion
Study: NCT00068731

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: lycopene
Study: NCT04512079

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Prophylactic enoxaparin (40 mg SC QD; 30 mg SC QD for CrCl \<30 mL/min) Full-dose enoxaparin (1 mg/kg SC Q12h; 1 mg/kg SC QD for CrCl \<30 mL/min)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Prophylactic enoxaparin (40 mg SC QD; 30 mg SC QD for CrCl \<30 mL/min) Full-dose enoxaparin (1 mg/kg SC Q12h; 1 mg/kg SC QD for CrCl \<30 mL/min)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: (5 mg Q12h; 2.5 mg Q12h for patients with at least two of three of age ≥80 years, weight ≤60 kg or serum creatinine ≥1.5 mg/dL)
Study: NCT02319980

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extracranial-intracranial bypass surgery
Description: All participants in this group will undergo combined cerebral revascularization surgery,namely superficial temporal to middle cerebral artery bypass (STA-MCA) and encephalo-duro-myo-synangiosis(EDMS)
Study: NCT01919112

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: Anodal tDCS will be administered with swallowing exercises
Study: NCT03007758

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open ventral hernia repair
Description: An open retromuscular ventral hernia repair involves an incision through your abdominal wall, most often through a prior surgery scar. The contents of the hernia, which may include intestine or fatty tissue, are returned into the abdominal cavity. The posterior (inner-most) layer of the abdominal wall is separated from the muscle and closed, which closes the abdominal cavity. Mesh is then placed over that closed layer, which is outside of the abdominal cavity, but below the abdominal muscles. The anterior (outer-most) layer of the abdominal wall is then closed over the mesh, which closes the hernia.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: robotic ventral hernia repair
Description: A robotic retromuscular ventral hernia repair involves a similar separation of the layers of the abdominal wall, similar mesh placement, and similar closure of the hernia defect. The surgical robot is a tool that allows your surgeon to place long, narrow instruments through small incisions in order to perform surgery from the inside of your abdomen. Rather than one longer incision in the middle of your abdomen, four to six small incisions, about 1 inch, are made along the outer part of your abdomen between the rib cage and hip.
Study: NCT01770587

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Insomnia Treatment
Study: NCT00548587

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: E5555

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: E5555

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: E5555

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01919112

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: Anodal tDCS will be administered with swallowing exercises

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Description: Anodal tDCS will be administered with swallowing exercises
Study: NCT02358538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganaxolone
Description: oral suspension or capsules
Study: NCT02659150

Intervention type: DRUG
Group type: OTHER
Intervention: tocilizumab
Description: subjects will be treated with 162mg of weekly subcutaneous tocilizumab in an open-label manner, this will be done addition to MTX or monotherapy. On subsequent weeks after the first dose of tocilizumab, subjects will be instructed to inject the full amount of syringe according to the directions provided in the Instructions For Use (IFU).
Study: NCT00551863

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: IVPT
Description: Violence prevention intervention based on Motivational Interviewing and CBT
Study: NCT01824472

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: Treatment for sleep apnea

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: Treatment for sleep apnea

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT
Description: Treatment for insomnia

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham CPAP
Description: Placebo for sleep apnea
Study: NCT01281306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AHU377
Description: AHU377 was supplied in tablets in blister cards in 50 mg and 100 mg strengths.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo was supplied as tablets in blister cards.
Study: NCT01824472

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CC
Description: Placebo (sham) for insomnia

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: CC
Description: Placebo (sham) for insomnia
Study: NCT03418896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: human chorionic gonadotropin
Description: a single injection of a standard dose
Study: NCT01815736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E/C/F/TAF
Description: 150/150/200/10 mg FDC tablet administered orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: E/C/F/TDF
Description: 150/150/200/300 mg FDC tablet administered orally once daily
Study: NCT04364581

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Women will be treated with letrozole (5 mg daily) for 10 days before hysteroscopic intervention

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Women will be treated with placebo for 10 days before hysteroscopic intervention
Study: NCT02111239

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CTA
Description: pelvic/abdominal CTA scan

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRA
Description: pelvic/abdominal MRA scan
Study: NCT03402906

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family-Clinician Collaboration Program
Description: Family-mediated treatment activities and collaboration between clinician and family members